Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Genetic changes in squamous cell lung cancer: a review.

Heist RS, Sequist LV, Engelman JA.

J Thorac Oncol. 2012 May;7(5):924-33. doi: 10.1097/JTO.0b013e31824cc334. Review.

2.

Genetic insight and therapeutic targets in squamous-cell lung cancer.

Sos ML, Thomas RK.

Oncogene. 2012 Nov 15;31(46):4811-4. doi: 10.1038/onc.2011.640. Review.

PMID:
22266863
3.

[Advances of molecular targeted therapy in squamous cell lung cancer].

Ma L, Zhang S.

Zhongguo Fei Ai Za Zhi. 2013 Dec;16(12):671-5. doi: 10.3779/j.issn.1009-3419.2013.12.10. Review. Chinese.

5.

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

Tanaka H, Hayashi A, Morimoto T, Taima K, Tanaka Y, Shimada M, Kurose A, Takanashi S, Okumura K.

BMC Cancer. 2012 Nov 26;12:558. doi: 10.1186/1471-2407-12-558.

6.

What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.

Cooper WA, O'toole S, Boyer M, Horvath L, Mahar A.

Pathology. 2011 Feb;43(2):103-15. doi: 10.1097/PAT.0b013e328342629d. Review.

PMID:
21233671
7.

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.

Dacic S.

J Clin Pathol. 2013 Oct;66(10):870-4. doi: 10.1136/jclinpath-2012-201336. Review.

PMID:
23801495
8.

Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).

Kumarakulasinghe NB, van Zanwijk N, Soo RA.

Respirology. 2015 Apr;20(3):370-8. doi: 10.1111/resp.12490. Review. Erratum in: Respirology. 2016 Apr;21(3):567.

9.

Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?

Ou SH.

J Clin Pathol. 2013 Oct;66(10):839-46. doi: 10.1136/jclinpath-2012-201296. Review.

PMID:
23661716
10.

Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.

Toyokawa G, Seto T.

Respir Investig. 2014 Nov;52(6):330-8. doi: 10.1016/j.resinv.2014.06.005. Review.

PMID:
25453376
11.

Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations.

Wang Z, Shen Z, Li Z, Duan J, Fu S, Liu Z, Bai H, Zhang Z, Zhao J, Wang X, Wang J.

Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):9990-5. doi: 10.1073/pnas.1510837112.

12.

[A case report: an EML4-ALK positive lung adenocarcinoma diagnosed 
with lymphoma previously].

Liu L, Heng W.

Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):89-91. doi: 10.3779/j.issn.1009-3419.2015.02.07. Chinese.

13.

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.

Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Review.

PMID:
23931927
14.

Targeting genomic alterations in squamous cell lung cancer.

Mantripragada K, Khurshid H.

Front Oncol. 2013 Aug 5;3:195. doi: 10.3389/fonc.2013.00195.

15.

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.

Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY.

Cancer Genet Cytogenet. 2007 Mar;173(2):107-13.

PMID:
17321325
16.

The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.

Rossi G, Graziano P, Leone A, Migaldi M, Califano R.

Semin Diagn Pathol. 2013 Nov;30(4):298-312. doi: 10.1053/j.semdp.2013.11.007. Review.

PMID:
24342286
17.

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.

Salido M, Pijuan L, Martínez-Avilés L, Galván AB, Cañadas I, Rovira A, Zanui M, Martínez A, Longarón R, Sole F, Serrano S, Bellosillo B, Wynes MW, Albanell J, Hirsch FR, Arriola E.

J Thorac Oncol. 2011 Jan;6(1):21-7. doi: 10.1097/JTO.0b013e3181fb7cd6.

18.

Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies.

Gerber DE, Paik PK, Dowlati A.

Am Soc Clin Oncol Educ Book. 2015:147-62. doi: 10.14694/EdBook_AM.2015.35.147. Review.

19.

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.

Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MR, Wang X, Peterson LM, Halling KC, Oliveira AM, Aubry MC, Yi ES.

Hum Pathol. 2009 Aug;40(8):1152-8. doi: 10.1016/j.humpath.2009.01.012.

PMID:
19386350
20.

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.

Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, Lin J, Chen S, Xie Z, Zhu M, Zhang X, Wu YL.

Mol Cancer. 2010 Jul 13;9:188. doi: 10.1186/1476-4598-9-188.

Supplemental Content

Support Center